• Maria Teresa “Tessa” Hilado will join Galderma’s Advisory Committee on January 1, 2022 

• Alchemee’s flagship brand Proactiv® is an iconic product synonymous with acne care

Lausanne – July 25, 2017 – Galderma announced today the enrollment of the first patient in a multicenter double-blind Phase IIb clinical trial to evaluate nemolizumab, its investigational subcutaneous anti-IL-31 receptor A (RA) monoclonal antibody, in patients with atopic dermatitis (AD).

Rewarding Patient Loyalty through Value Incentive Offer on Restylane® Treatments from Aesthetic Professionals

• Launching in May, an inaugural four-part webinar series Unmasking Facial Skin & Dermatoses will feature expert presentations from world-renowned dermatologists
• The program launches the Galderma Excellence in Multichannel Medical Education (GEMME) platform, demonstrating its commitment to innovative and science-led approaches in skin health